ArticleFrontiers in oncology2026
Early clinical determinants of adverse outcomes in paediatric febrile neutropenia: a prospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Febrile neutropenia (FN) remains a major cause of morbidity and mortality in paediatric haemato-oncology, but routinely available determinants of adverse in-hospital outcome remain incompletely characterised. We aimed to identify baseline clinical, haematological, biochemical, and microbiological factors associated with in-hospital mortality and prolonged fever. Methods: We conducted a prospective single-centre cohort study of 90 consecutive FN admissions in paediatric haemato-oncology patients. Thirty-nine prespecified baseline predictors were evaluated using Firth penalised-likelihood logistic regression. Multivariable models were prespecified on clinical grounds, and discrimination was internally validated using 500 bootstrap replicates with optimism correction. Prolonged fever was defined as time to defervescence >5 days, with death before defervescence counted as an event. Results: Of 86 mortality-evaluable episodes, 16 children died in hospital (18.6%). In the multivariable mortality model, any respiratory support (adjusted odds ratio [aOR], 11.9; 95% CI, 2.5-56.9) and lower admission albumin (aOR, 0.29 per 1 g/dL increase; 95% CI, 0.11-0.77) showed the strongest associations with death. Active disease (aOR 3.5, 95% CI 0.87-14.2) and gram-negative bacteraemia (aOR 4.2, 95% CI 0.93-18.9) showed directionally adverse but imprecise associations. The bootstrap-corrected AUC was 0.88. Of 60 classifiable episodes for the secondary outcome, 31 (51.7%) had prolonged fever. Prolonged fever was associated with older age (aOR 1.24 per year, 95% CI 1.05-1.48), lower albumin (aOR 0.31 per 1 g/dL increase, 95% CI 0.12-0.82), any respiratory support (aOR 10.0, 95% CI 0.98-102.0), and gram-negative bacteraemia (aOR 5.5, 95% CI 1.01-30.3). The bootstrap-corrected AUC was 0.85. Neutropenia depth and platelet count were not independently associated with either outcome. Conclusion: In paediatric haemato-oncology patients with FN, adverse in-hospital outcomes were associated mainly with early or evolving respiratory compromise, lower admission albumin, active disease, and gram-negative bacteraemia. Three of these factors, together with age, were associated with prolonged fever or death before defervescence among classifiable episodes. Albumin should be interpreted as a dynamic marker of acute inflammatory burden, capillary leak, and host reserve rather than as a standalone nutritional measure. These routinely available variables may support exploratory bedside risk appraisal, but external validation is required before clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.